Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
13%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph early_phase_1
1
8%
Ph phase_1
1
8%
Ph phase_4
4
33%
Ph not_applicable
3
25%
Ph phase_3
1
8%
Ph phase_2
1
8%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
4(36.4%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(3)
Other(1)

Detailed Status

Completed8
Withdrawn2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (9.1%)
Phase 11 (9.1%)
Phase 21 (9.1%)
Phase 31 (9.1%)
Phase 44 (36.4%)
N/A3 (27.3%)

Trials by Status

terminated18%
withdrawn217%
completed867%
unknown18%

Recent Activity

0 active trials
Showing 5 of 12
withdrawnphase_3

A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

NCT06260748
completedphase_1

Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)

NCT06180057
completed

Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

NCT05499026
completedphase_4

Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

NCT03168555
completedphase_4

Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

NCT02876484
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06260748Phase 3

A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

Withdrawn
NCT06180057Phase 1

Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)

Completed
NCT05499026

Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

Completed
NCT03168555Phase 4

Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

Completed
NCT02876484Phase 4

Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Completed
NCT02952963Phase 4

Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Completed
NCT02340247Phase 4

Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Completed
NCT00004442Not Applicable

Study of Bile Acids in Patients With Peroxisomal Disorders

Terminated
NCT01666223Not Applicable

Effect of Bile Acids on GLP-1 Secretion

Completed
NCT00018694Not Applicable

Cholestanol in Humans

Withdrawn
NCT00465751Early Phase 1

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

Completed
NCT00004346Phase 2

Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12